Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to those derived from adult peripheral blood mononuclear cells (PBMCs). Key findings include longer telomeres and attenuated cytokine responses without loss of cytotoxicity. These advantages may lead to more effective and scalable CAR-T therapies. Dr. Robert Hariri, CEO of Celularity, emphasized the potential of their platform to deliver improved and durable allogeneic CAR-T products.
- CAR-T cells from Celularity's platform showed greater persistence and resistance to exhaustion.
- The study reported longer telomeres in CAR-T cells from the placental platform.
- Attenuated cytokine response observed without loss of cytotoxicity.
- Potential for improved and prolonged in vivo efficacy and persistence.
- Celularity's platform offers scalability and consistency in manufacturing, potentially improving economics.
- Promising prospects for developing more effective and safer CAR-T therapies.
- No specific clinical outcomes or financial impacts were reported.
- Data to in vivo studies; potential need for further clinical trials.
- Possible market skepticism due to the early-stage nature of the findings.
- No immediate financial gains or partnerships announced.
Insights
The publication of Celularity's data in a prestigious journal underscores the scientific significance of their findings. Placental T cells demonstrated better persistence and resistance to exhaustion compared to traditional methods. This suggests a promising advancement in CAR-T therapy, potentially leading to longer-lasting and more effective treatments for cancer patients.
Moreover, the attenuation of cytokine response without loss of cytotoxicity is particularly compelling as it indicates a potentially lower risk of severe side effects such as cytokine release syndrome, a common complication in CAR-T treatments. This could improve the safety profile of CAR-T therapies significantly.
Celularity’s focus on placental-derived T cells for CAR-T therapy is noteworthy given the unique attributes of these cells. The study highlights longer telomeres and retained stemness, which are important for cell longevity and functionality. These characteristics could translate to better patient outcomes through more durable and persistent therapeutic effects.
This also suggests a potential shift in the industry towards utilizing placental cells, which might impact future research and development strategies. The scalability mentioned by Celularity could lead to cost efficiencies and broader accessibility for these advanced therapies, which has been a significant barrier thus far.
From a financial perspective, the potential scalability and consistency in manufacturing of Celularity’s placental T cells could be transformative. This could lower production costs and improve margins, making these therapies more economically viable. Investors should note the importance of this for long-term sustainability and market positioning in the competitive CAR-T space.
Furthermore, the promising data could attract partnerships and funding opportunities, leveraging Celularity’s advanced manufacturing capabilities. However, one should be cautious and consider that these findings are still in the early stages of clinical validation and market application. The success in clinical trials and regulatory approvals will be important to realizing these benefits.
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells
FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity’s T-Cell platform for future immunotherapies including chimeric antigen receptor (CAR-T) therapies.
The data compared CAR-T cells derived from Celularity’s proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs). CAR-T cells generated from its T-Cell platform retained stemness, maintained longer telomeres, and were more resistant to both exhaustion and immune checkpoint upregulation. Additionally, an attenuated cytokine response was observed without loss of cytotoxicity. This translated into improved and prolonged in vivo efficacy and persistence compared with healthy, adult PBMC-derived CAR-T.
"These findings help differentiate the placenta as a source of cells for immunotherapy and demonstrate the valuable potential of our placental platform for allogeneic CAR-T products," said Dr. Robert Hariri, founder, Chairman and CEO of Celularity. "As the field of cellular immunotherapy moves towards delivering ‘one-size-fits-all’ allogeneic products, the stemness advantages inherent in our platform have the potential to translate into improved persistence and durable activity with an enhanced safety profile, offering promising prospects for developing more effective CAR-T therapies in the future. Moreover, we believe that our placental platform offers a level of scalability and consistency in manufacturing which can significantly impact the economics of delivering these therapies in the future. Through our state-of-the-art manufacturing and technical infrastructure, Celularity can be an ideal development and manufacturing partner in the cellular medicine industry."
About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include, without limitation, the potential advantages of Celularity’s T-Cell platform for future immunotherapies including CAR-T therapies, the potential value of Celularity’s cells as a source for allogeneic CAR-T products, the inherent stemness advantages in Celularity’s proprietary placental platform, the ability of Celularity’s CAR-T therapies to improve persistence and durable activity with an enhanced safety profile relative to PBMC derived CAR-T therapies, Celularity’s ability to offer promising prospects for developing more effective CAR-T therapies, the ability of Celularity’s placental platform to offer levels of scalability and manufacturing consistency to improve the costs, and Celularity’s ability to act as a cost effective, highly scalable development and manufacturing partner in the cellular medicine industry, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity’s liquidity situation; the volatility in Celularity’s stock price; inherent risks in biotechnological development, including with respect to the development of novel cellular therapies; along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
Carlos Ramirez
Celularity Inc.
carlos.ramirez@celularity.com
Media Contacts
Patrick Maddox / Michaela Fawcett
KCSA Strategic Communications
pmaddox@kcsa.com / mfawcett@kcsa.com
FAQ
What benefits do Celularity's placental-derived T cells offer for CAR-T therapy?
How do CAR-T cells from Celularity's platform compare to those from adult PBMCs?
What are the potential advantages of Celularity's placental platform for CAR-T therapies?
What did the data published in the Journal for ImmunoTherapy of Cancer reveal about Celularity's T-Cell platform?
